Frontotemporal Dementia
Frontotemporal Dementia (FTD) is a progressive neurodegenerative disorder characterized by degeneration of the frontal and temporal lobes of the brain, leading to progressive impairment in behavior, personality, executive function, and language. Unlike Alzheimer's disease, FTD commonly affects individuals at a younger age and currently lacks any approved disease-modifying therapy.
Frontotemporal Dementia Epidemiology Segmentation
<ul>
<li dir="ltr" aria-level="1">
Diagnosed Prevalent Cases
</li>
<li dir="ltr" aria-level="1">
Type-specific Diagnosed Prevalent Cases
</li>
<li dir="ltr" aria-level="1">
Mutation-specific Diagnosed Prevalent Cases
</li>
<li dir="ltr" aria-level="1">
Gene-specific Diagnosed Prevalent Cases
</li>
</ul>
Frontotemporal Dementia Epidemiology
<ul>
<li dir="ltr" aria-level="1">
Across the 7 Major Markets (7MM), the total diagnosed prevalent population of Frontotemporal Dementia was estimated at approximately 130K cases in 2025.
</li>
<li dir="ltr" aria-level="1">
The regional distribution of diagnosed prevalent cases was United States (46%), EU4 and the UK (45%), and Japan (9%).
</li>
<li dir="ltr" aria-level="1">
Frontotemporal Dementia represents approximately 10&ndash;20% of all dementia cases, making it one of the leading causes of early-onset dementia.
</li>
<li dir="ltr" aria-level="1">
The diagnosed patient population is expected to increase during the forecast period owing to improved disease awareness, advances in genetic testing, and increasing adoption of biomarker-supported diagnosis.
</li>
</ul>
<h2 dir="ltr">Frontotemporal Dementia Market</h2>
<ul>
<li dir="ltr" aria-level="1">
Within the 7 Major Markets (7MM), the United States accounted for approximately 70% of the Frontotemporal Dementia market in 2025.
</li>
<li dir="ltr" aria-level="1">
The Frontotemporal Dementia market size across the 7MM was estimated at approximately USD 120 million in 2025.
</li>
<li dir="ltr" aria-level="1">
The market is projected to grow at a CAGR of approximately 15% during the forecast period (2026&ndash;2036).
</li>
<li dir="ltr" aria-level="1">
The Frontotemporal Dementia market is expected to expand significantly with the anticipated launch of disease-modifying therapies, increasing clinical awareness, improved diagnosis, and ongoing research activities.
</li>
<li dir="ltr" aria-level="1">
Latozinemab, the leading investigational therapy for FTD-GRN, has received Orphan Drug Designation (ODD), Breakthrough Therapy Designation (BTD), and Fast Track Designation, highlighting strong regulatory momentum and future commercial potential.
</li>
</ul>
Frontotemporal Dementia Market Drivers
<ul>
<li dir="ltr" aria-level="1">
Increasing prevalence and improved diagnosis are expanding the identifiable patient population.
</li>
<li dir="ltr" aria-level="1">
Growing awareness among healthcare professionals is supporting earlier recognition and referral.
</li>
<li dir="ltr" aria-level="1">
Advancements in biomarker research and genetic testing are improving diagnostic accuracy.
</li>
<li dir="ltr" aria-level="1">
A strong pipeline of disease-modifying therapies is expected to transform the future treatment landscape.
</li>
</ul>
Frontotemporal Dementia Market Barriers
<ul>
<li dir="ltr" aria-level="1">
There are currently no approved disease-modifying therapies, leaving significant unmet clinical needs.
</li>
<li dir="ltr" aria-level="1">
Clinical and genetic heterogeneity complicate patient stratification and targeted drug development.
</li>
<li dir="ltr" aria-level="1">
The absence of reliable biomarkers for disease progression continues to hinder diagnosis and clinical trial success.
</li>
<li dir="ltr" aria-level="1">
Limited awareness among clinicians frequently results in delayed diagnosis and suboptimal patient management.
</li>
</ul>
Emerging Frontotemporal Dementia Drugs
<ul>
<li dir="ltr" aria-level="1">
VES001
</li>
<li dir="ltr" aria-level="1">
TAK-594 (DNL593)
</li>
<li dir="ltr" aria-level="1">
AVB-101
</li>
<li dir="ltr" aria-level="1">
PBFT02
</li>
<li dir="ltr" aria-level="1">
And others
</li>
</ul>
Key Frontotemporal Dementia Companies
<ul>
<li dir="ltr" aria-level="1">
Vesper Bio
</li>
<li dir="ltr" aria-level="1">
Denali Therapeutics
</li>
<li dir="ltr" aria-level="1">
Takeda
</li>
<li dir="ltr" aria-level="1">
AviadoBio
</li>
<li dir="ltr" aria-level="1">
Passage Bio
</li>
<li dir="ltr" aria-level="1">
Alector
</li>
<li dir="ltr" aria-level="1">
Wave Life Sciences
</li>
<li dir="ltr" aria-level="1">
Prevail Therapeutics
</li>
<li dir="ltr" aria-level="1">
And others.
</li>
</ul>
&nbsp;

Frontotemporal Dementia Market

Frontotemporal Dementia Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape.